CS
BCYC

Candriam SCA’s Bicycle Therapeutics BCYC Stock Holding History

Candriam SCA’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,192,279
Closed -$8.44M – 697
2025
Q4 		$8.44M Buy
1,192,279
+19,892
+2% +$147K 0.04% 290
2025
Q3 		$9.07M Hold
1,172,387
– – 0.05% 286
2025
Q2 		$8.15M Sell
1,172,387
-32,820
-3% -$261K 0.05% 279
2025
Q1 		$10.2M Buy
1,205,207
+117,331
+11% +$1.38M 0.06% 235
2024
Q4 		$15.2M Buy
1,087,876
+37,278
+4% +$799K 0.09% 207
2024
Q3 		$23.8M Buy
1,050,598
+291,418
+38% +$6.72M 0.14% 154
2024
Q2 		$15.4M Sell
759,180
-130,078
-15% -$2.94M 0.09% 207
2024
Q1 		$22.1M Buy
889,258
+20,000
+2% +$425K 0.14% 151
2023
Q4 		$15.7M Sell
869,258
-384,003
-31% -$6.35M 0.11% 190
2023
Q3 		$25.2M Sell
1,253,261
-20,000
-2% -$457K 0.18% 114
2023
Q2 		$32.5M Sell
1,273,261
-29,950
-2% -$696K 0.23% 110
2023
Q1 		$25.5M Buy
1,303,211
+128,000
+11% +$3.21M 0.18% 138
2022
Q4 		$34.8M Sell
1,175,211
-57,043
-5% -$1.53M 0.23% 100
2022
Q3 		$28.7M Buy
1,232,254
+397,578
+48% +$9.46M 0.2% 113
2022
Q2 		$14M Buy
+834,676
New +$17.6M 0.12% 180

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Candriam SCA's BCYC Position: Q1 2026 in Review

Candriam SCA sold out of Bicycle Therapeutics (BCYC) in Q1 2026, closing a stake of 1,192,279 shares — an estimated $8.44M sold.

Candriam SCA first reported a position in BCYC in Q2 2022 and held it in 15 quarters. The position peaked at $34.8M in Q4 2022. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Candriam SCA reported no remaining Bicycle Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Candriam SCA sold 1,192,279 Bicycle Therapeutics shares in Q1 2026, an estimated $8.44M.
  • Candriam SCA first reported a position in Bicycle Therapeutics in Q2 2022 and held it in 15 quarters.
  • Candriam SCA's Bicycle Therapeutics position peaked at $34.8M in Q4 2022.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.